MX2019003731A - Métodos para diagnosticar y tratar el cáncer de próstata metastásico resistente a la castración resistente o sensible al tratamiento con acetato de abiraterona-glucocorticoide. - Google Patents

Métodos para diagnosticar y tratar el cáncer de próstata metastásico resistente a la castración resistente o sensible al tratamiento con acetato de abiraterona-glucocorticoide.

Info

Publication number
MX2019003731A
MX2019003731A MX2019003731A MX2019003731A MX2019003731A MX 2019003731 A MX2019003731 A MX 2019003731A MX 2019003731 A MX2019003731 A MX 2019003731A MX 2019003731 A MX2019003731 A MX 2019003731A MX 2019003731 A MX2019003731 A MX 2019003731A
Authority
MX
Mexico
Prior art keywords
glucocorticoid
abiraterone acetate
resistant
prostate cancer
diagnosing
Prior art date
Application number
MX2019003731A
Other languages
English (en)
Inventor
Li Weimin
Kawaguchi Kazushiro
Oyama Ryo
Patel Jaymala
SMIRNOV Denis
Ricci Deborah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019003731A publication Critical patent/MX2019003731A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente descripción se describen biomarcadores novedosos para detectar resistencia y sensibilidad al tratamiento con acetato de abiraterona-glucocorticoide en un paciente que tiene cancer de prostata metastasico resistente a la castracion. También se proporcionan métodos para diagnosticar y tratar el cáncer de próstata metastasico resistente a la castración resistente al acetato de abiraterona-glucocorticoide y sensible al acetato de abiraterona-glucocorticoide.
MX2019003731A 2016-09-30 2017-09-29 Métodos para diagnosticar y tratar el cáncer de próstata metastásico resistente a la castración resistente o sensible al tratamiento con acetato de abiraterona-glucocorticoide. MX2019003731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402196P 2016-09-30 2016-09-30
PCT/US2017/054286 WO2018064470A1 (en) 2016-09-30 2017-09-29 Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Publications (1)

Publication Number Publication Date
MX2019003731A true MX2019003731A (es) 2019-07-01

Family

ID=60186369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003731A MX2019003731A (es) 2016-09-30 2017-09-29 Métodos para diagnosticar y tratar el cáncer de próstata metastásico resistente a la castración resistente o sensible al tratamiento con acetato de abiraterona-glucocorticoide.

Country Status (15)

Country Link
US (1) US20180092930A1 (es)
EP (1) EP3519591A1 (es)
JP (1) JP7197470B2 (es)
KR (1) KR20190056420A (es)
CN (1) CN109790586A (es)
AU (1) AU2017336917A1 (es)
BR (1) BR112019006404A2 (es)
CA (1) CA3038964A1 (es)
EA (1) EA201990847A1 (es)
IL (1) IL265675A (es)
JO (1) JOP20190067A1 (es)
MX (1) MX2019003731A (es)
PH (1) PH12019500675A1 (es)
SG (1) SG10201912521PA (es)
WO (1) WO2018064470A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115004031A (zh) * 2019-12-27 2022-09-02 富士胶片株式会社 辅助诊断转移性雄激素阻断疗法抗性前列腺癌的方法
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9766244B2 (en) * 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en) * 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
CA2915904A1 (en) * 2013-08-21 2015-02-26 Curevac Ag Composition and vaccine for treating prostate cancer
US20150110814A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
US20150147339A1 (en) * 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
US20160011198A1 (en) 2014-01-27 2016-01-14 Epic Sciences, Inc. Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
CN106661615A (zh) 2014-05-12 2017-05-10 詹森药业有限公司 用于鉴定患者以使用醋酸阿比特龙进行治疗的生物标志物

Also Published As

Publication number Publication date
PH12019500675A1 (en) 2019-12-02
IL265675A (en) 2019-05-30
KR20190056420A (ko) 2019-05-24
EP3519591A1 (en) 2019-08-07
AU2017336917A1 (en) 2019-04-11
JOP20190067A1 (ar) 2019-03-28
US20180092930A1 (en) 2018-04-05
WO2018064470A1 (en) 2018-04-05
JP7197470B2 (ja) 2022-12-27
JP2019530452A (ja) 2019-10-24
SG10201912521PA (en) 2020-02-27
CN109790586A (zh) 2019-05-21
EA201990847A1 (ru) 2019-08-30
CA3038964A1 (en) 2018-04-05
BR112019006404A2 (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
PH12019500675A1 (en) Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
BR112017018008A2 (pt) ?métodos de prognóstico e/ou diagnóstico do câncer, para determinação da dosagem de um produto, para adaptar a dosagem de um produto, para determinar os efeitos benéficos e/ou adversos de uma substância, para identificar um paciente como respondedor a um tratamento, para identificar um paciente como não respondedor a um tratamento, para tratar o câncer, meios para prognosticar e/ou diagnosticar, kit, uso dos meios e dispositivo para a identificação de câncer?
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
IL276748A (en) Methods for the detection and treatment of prostate cancer
MX2019005683A (es) Metodos para detectar mutaciones de adn mediante el uso de extraccion con puntas mitra.
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
EP2959291A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER BY DETECTION AND MANIPULATION OF MICROBES IN TUMORS
WO2018183817A3 (en) Tumor burden as measured by cell free dna
IL269552A (en) Diagnostic methods and kits for early detection of ovarian cancer
MX2016013910A (es) Tratamiento del cancer.
IL276089A (en) Methods for colon cancer detection and treatment monitoring
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX362049B (es) Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
IN2015DN01646A (es)